Topical review on nano-vaccinology: Biochemical promises and key challenges

Zaheer, Tean; Pal, Kaushik; Zaheer, Iqra

doi:10.1016/j.procbio.2020.09.028

Cited by 41 publications

(14 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, as a new scientific material, nanomaterials constitute ambient ultrafine particles (UFPs) and engineered nanoparticles (ENPs) ( Pollard, 2020 ). Nanomaterials are versatile in prevention, treatment and control of diseases ( Zaheer et al, 2021 ). Actually, nanomaterials are beneficial to autoimmune diseases.…”

Section: Future Expectationmentioning

confidence: 99%

The Pathological Mechanism and Potential Application of IL-38 in Autoimmune Diseases

et al. 2021

View full text Add to dashboard Cite

Interleukin-38 (IL-38), a new cytokine of interleukin-1 family (IL-1F), is expressed in the human heart, kidney, skin, etc. Recently, new evidence indicated that IL-38 is involved in the process of different autoimmune diseases. Autoimmune diseases are a cluster of diseases accompanied with tissue damage caused by autoimmune reactions, including rheumatoid arthritis (RA), psoriasis, etc. This review summarized the links between IL-38 and autoimmune diseases, as well as the latest knowledge about the function and regulatory mechanism of IL-38 in autoimmune diseases. Especially, this review focused on the differentiation of immune cells and explore future prospects, such as the application of IL-38 in new technologies. Understanding the function of IL-38 is helpful to shed light on the progress of autoimmune diseases.

show abstract

Section: Future Expectationmentioning

confidence: 99%

The Pathological Mechanism and Potential Application of IL-38 in Autoimmune Diseases

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Many pathogens, particularly viruses, fall within this size range, which means the host immune system has evolved to deal with particles in this size range [42]. Nanoparticles can be engineered to interact with different immune cells, such as B-cells and/or phagocytic cells making them an excellent platform for vaccine development [43]. Most nanovaccines are decorated on their surface with antigens of interest allowing for direct interaction with B-cell receptors; however, some can carry antigens, or immunostimilatory molecules encapsulated or as a structural feature of the particle itself [44].…”

Section: Nanovaccinesmentioning

confidence: 99%

The current and future role of nanovaccines in HIV-1 vaccine development

Karch

Matyas

2021

Expert Review of Vaccines

View full text Add to dashboard Cite

Introduction: An efficacious vaccine for HIV-1 has been sought for over 30 years to eliminate the virus from the human population. Many challenges have occurred in the attempt to produce a successful immunogen, mainly caused by the basic biology of the virus. Immunogens have been developed focusing on inducing one or more of the following types of immune responses; neutralizing antibodies, non-neutralizing antibodies, and T-cell mediated responses. One way to better present and develop an immunogen for HIV-1 is through the use of nanotechnology and nanoparticles.Areas covered: This article gives a basic overview of the HIV-1 vaccine field, as well as nanotechnology, specifically nanovaccines. It then covers the application of nanovaccines made from biological macromolecules to HIV-1 vaccine development for neutralizing antibodies, non-neutralizing antibodies, and T-cell-mediated responses. Expert opinion: Nanovaccines are an area that is ripe for further exploration in HIV-1 vaccine field. Not only are nanovaccines capable of carrying and presenting antigens in native-like conformations, but they have also repeatedly been shown to increase immunogenicity over recombinant antigens alone. Only through further research can the true role of nanovaccines in the development of an efficacious HIV-1 vaccine be established.

show abstract

“…Vaccine design seeks to ensure that host adaptative immunity be long-lasting and highly specific, thereby enabling it to act against possible reinfections [ 36 ]. The main strengths derived from using nanovaccines has been dealt with in the pertinent literature [ 72 , 73 , 74 ]. The NP-based vaccine approach (nanovaccines) is very promising because of the great advantages offered by being properly captured by the immune system cells.…”

Section: An Effective Broad-coverage Immune Responsementioning

confidence: 99%

“…Other aspects such as increased antigen stability and reduced degradation have led to nanovaccines triggering sustained antigen release (i.e., creating an antigen reservoir), meaning that the time of remaining at the application site lasts longer, thereby facilitating immune cell action [ 73 ]. Concerning particle size, a diameter of up to 10 µm enables them to enter cells by endocytosis (mainly observed in macrophages) [ 26 , 74 ].…”

Section: An Effective Broad-coverage Immune Responsementioning

confidence: 99%

Nanovaccines against Animal Pathogens: The Latest Findings

et al. 2021

View full text Add to dashboard Cite

Nowadays, safe and efficacious vaccines represent powerful and cost-effective tools for global health and economic growth. In the veterinary field, these are undoubtedly key tools for improving productivity and fighting zoonoses. However, cases of persistent infections, rapidly evolving pathogens having high variability or emerging/re-emerging pathogens for which no effective vaccines have been developed point out the continuing need for new vaccine alternatives to control outbreaks. Most licensed vaccines have been successfully used for many years now; however, they have intrinsic limitations, such as variable efficacy, adverse effects, and some shortcomings. More effective adjuvants and novel delivery systems may foster real vaccine effectiveness and timely implementation. Emerging vaccine technologies involving nanoparticles such as self-assembling proteins, virus-like particles, liposomes, virosomes, and polymeric nanoparticles offer novel, safe, and high-potential approaches to address many vaccine development-related challenges. Nanotechnology is accelerating the evolution of vaccines because nanomaterials having encapsulation ability and very advantageous properties due to their size and surface area serve as effective vehicles for antigen delivery and immunostimulatory agents. This review discusses the requirements for an effective, broad-coverage-elicited immune response, the main nanoplatforms for producing it, and the latest nanovaccine applications for fighting animal pathogens.

show abstract

Topical review on nano-vaccinology: Biochemical promises and key challenges

Abstract: Highlights Nano-vaccines have promising potential to be materialized for personalized medical care Description of biological mechanisms for interaction making nano-vaccines successful Future insights for commercial up-scaling

Cited by 41 publications

References 69 publications

The Pathological Mechanism and Potential Application of IL-38 in Autoimmune Diseases

The Pathological Mechanism and Potential Application of IL-38 in Autoimmune Diseases

The current and future role of nanovaccines in HIV-1 vaccine development

Nanovaccines against Animal Pathogens: The Latest Findings

Contact Info

Product

Resources

About